Drug Profile
Research programme: cardiovascular therapies - Cardurion Pharmaceuticals/Takeda
Alternative Names: CaM kinase II - Cardurion Pharmaceuticals; CaMKII inhibitor - Cardurion PharmaceuticalsLatest Information Update: 17 Feb 2022
Price :
$50
*
At a glance
- Originator Cardurion Pharmaceuticals; Takeda
- Class Cardiovascular therapies; Heart failure therapies
- Mechanism of Action Calmodulin antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cardiovascular disorders; Heart failure